<DOC>
	<DOC>NCT01859949</DOC>
	<brief_summary>To assess the long-term safety of Genotropin(somatropin) on Small for Gestational Age (SGA) without epiphyseal closing.</brief_summary>
	<brief_title>Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<criteria>Children with short stature due to SGA who received treatment in the study GENASG0021002. Children who have any chronic disease requiring treatment with steroid hormone that may affect growth promotion including estrogen, androgen, anabolic hormone, and corticosteroids (except those for external use), and have received the treatment. Children who have received radiotherapy or chemotherapy. Children who have serious cardiac disease, renal disease, or hepatic disease. Children who have diabetes mellitus with a manifestation of abnormal glucose metabolism. Children who have serious chronic disease. Children who have malignant tumor. Children who are allergic to mcresol.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Genotropin(somatropin)</keyword>
	<keyword>SGA</keyword>
	<keyword>Short Stature</keyword>
	<keyword>Long-term</keyword>
	<keyword>Safety</keyword>
</DOC>